This week, Dr. Daniel Bloomfield from Anthos Therapeutics discusses the prevalence and dangers of blood clots, particularly in patients with cancer. Dr. Bloomfield explains the difference between normal and abnormal blood clotting, the risks associated with blood clots in arteries and veins, and the challenges in balancing clot prevention with the risk of bleeding. 

Dr. Lishan Aklog from Lucid Diagnostics tells us about the path from GERD to, unfortunately, esophageal cancer, and about Lucid’s two-minute diagnostic test which can detect precancerous cells. 

Dr. Eric Merle from GenoSkin talks about how they are transforming drug discovery using discarded human skin from surgeries like tummy tucks, revolutionizing the process and accelerating drug development timelines.

Tech Nation Health Chief Correspondent Dr. Daniel Kraft talks about the newest XPrize worth an unprecedented $101 Million.

Dr. Nik Sopko, the Chief Scientific Officer of PolarityTE talks about their design for wound healing. Their first treatment candidate is diabetic foot ulcers.

Dr. Eric Vivier from Innate Pharma in Marseilles tells us about the next wave of immunotherapy treatments – harnessing Natural Killer cells.

Dr. Ray Stevens, CEO of ShouTi Pharma, talks about their approach in turning IV drugs into pills. Current projects include Diabetes and obesity, and two Pulmonary and Cardiovascular disorders. And these are just their first candidates …

Dr. Stewart Campbell, CEO of Axial Therapeutics, about their groundbreaking work in Autism–related irritability in teenagers, in Parkinson’s, and in complementing the latest cancer treatments.

On this week’s BioTech Nation University of Chicago professor Dr. Neil Shubin talks about his book “Some Assembly required … Decoding Four Billion Years of Life, from Ancient Fossils to DNA.” Ancient viruses in our DNA? And what about “jumping genes”?

This week we visit the brain, and look at what a flexible brain implant might do – from sensing how your brain is working to actual treatment. Nicolas Vachicouras from Neurosoft Bioelectronics in Geneva, Switzerland talks about the target for their first treatment: severe tinnitus.